About Us

Embracing innovation, exploration, and the very latest cutting-edge technologies, we are committed to technological and scientific advancement that can benefit the global community.


Refusing to compromise when it comes to ethics, compliance, and transparency, we develop platforms dedicated to cellular production, stem cell differentiation, and micro-physiological modelling for in vitro research and drug discovery.

What We Do

Stemnovate’s compliant organs-on-chip platforms integrate stem cell research and tissue engineering to provide physiological alternative to cancer lines and animal models for precision drug discovery and screening.

It takes, on average, 10-15 years to launch a new drug, costing approximately 5 billion USD. And, with costs increasing year on year, many in the pharmaceutical industry feel this trend is untenable. With this level of investment in terms of time, resources, and funds, the occurrence of drug failures and market withdrawals can have a substantial financial impact, as well as posing a significant level of risk to the health of patients.


Our platform technology provides an opportunity to execute the vision of high-throughput and cost-effective drug discovery.

Watch this introductory short video about Stemnovate

Current pharma approaches as used in ADMET ( Absorption, Distribution, Metabolism, Excretion and Toxicity) screening prior to and during clinical trials, rely on human and animal hepatocytes, with primary human hepatocytes regarded as the gold standard for testing. But primary liver cells are a limited resource, in UK, there are 587 people on the waiting list for a liver transplant, 129 of whom had been waiting longer than a year.  An adult waits on average 137 days and a child 74 days.


Moreover, the primary hepatocytes in laboratory are difficult to propagate and show marked reduction of functionality – compromising drug metabolism and diminishing model effectiveness. Another problem with such systems is lack of reproducibility.


The  cell lines used as an alternative lack genomic variation in study model. Therefore, better tools are needed to assess toxic liability in new drugs, earlier on in the development process.